Akero Therapeutics Inc Market Cap ($4.50 Billion)
Market Cap & Net Worth: Akero Therapeutics Inc (AKRO)
Akero Therapeutics Inc market cap. Akero Therapeutics Inc (NASDAQ:AKRO) has a market capitalization of $4.50 Billion ($4.50 Billion) as of October 30, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3723 globally and #1332 in its home market, demonstrating a 0.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Akero Therapeutics Inc's stock price $54.65 by its total outstanding shares 82324445 (82.32 Million).
Akero Therapeutics Inc Market Cap History (2019–2025)
Akero Therapeutics Inc market cap history from 2019 to 2025. Data shows growth from $1.83 Billion to $4.50 Billion (18.38% CAGR). Check AKRO stock price for real-time trading data and today's change.
Index Memberships
Akero Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.17% | #101 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.01% | #434 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.24% | #66 of 263 |
Weight: Akero Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Akero Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Akero Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Akero Therapeutics Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AKRO by Market Capitalization
Companies near Akero Therapeutics Inc in the global market cap rankings as of October 30, 2026. See Akero Therapeutics Inc balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Akero Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Akero Therapeutics Inc (2019–2025)
Market capitalization of Akero Therapeutics Inc from 2019 to today. Between 2019 and today, Akero Therapeutics Inc's market cap moved from $1.83 Billion to $ 4.50 Billion, with a yearly change of 18.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.50 Billion | +96.44% |
| 2024 | $2.29 Billion | +19.14% |
| 2023 | $1.92 Billion | -57.39% |
| 2022 | $4.51 Billion | +159.10% |
| 2021 | $1.74 Billion | -18.02% |
| 2020 | $2.12 Billion | +16.24% |
| 2019 | $1.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Akero Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.50 Billion USD |
| MoneyControl | $4.50 Billion USD |
| MarketWatch | $4.50 Billion USD |
| marketcap.company | $4.50 Billion USD |
| Reuters | $4.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic… Read more